MK 1029

Drug Profile

MK 1029

Alternative Names: MK1029

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antiallergics; Antiasthmatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma
  • No development reported Allergic asthma

Most Recent Events

  • 30 Aug 2017 Merck Sharp & Dohme completes a phase II trial for Asthma in Japan, Malaysia, Poland, South Africa and Guatemala (NCT02720081)
  • 22 Mar 2016 Merck Sharp & Dohme plans a phase II trial for Asthma in USA (PO) (NCT02720081)
  • 29 Dec 2015 No recent reports on development identified - Phase-I for Allergic asthma in United Kingdom (PO, capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top